Horizon Therapeutics responded to the FTC’s complaint against Amgen’s acquisition, stating that the deal could enhance access to rare disease medicines for more patients. They denied any plans to bundle medicines and emphasized the importance of advocating for innovative treatments. They aim to close the transaction by mid-December.
Horizon Therapeutics plc (Nasdaq: HZNP) today issued the following statement in response to the FTC’s complaint seeking to block Amgen’s proposed acquisition of the Company:
“This acquisition has the potential to accelerate the availability of important rare disease medicines to more patients worldwide. The FTC’s complaint impacts patients and is rooted in a theory about potential future “bundled” contracts with payors and not competitive overlap concerns. Horizon does not and has no plans to bundle any of its rare disease medicines. It is imperative that we continue to advocate for access to innovative treatments for patients who may benefit, particularly in diseases with significant unmet needs, and the proposed transaction with Amgen is part of that mission. We firmly believe in the benefits of this acquisition and intend to work with the court on a schedule that would allow the transaction to close by mid-December.”
Source: BioSpace
Want to publish your own articles on DistilINFO Publications?
Send us an email, we will get in touch with you.
